News

Orkambi’s anti-inflammatory benefits seen in a real-world study

Beyond improving lung function, Orkambi (ivacaftor/lumacaftor) has potent anti-inflammatory benefits that may limit immune-related lung damage in people with cystic fibrosis (CF), according to a real-world study. Researchers found that one year of treatment significantly reduced the levels of pro-inflammatory signaling molecules in the bloodstream and airways of…

Patients able to reduce supportive therapies after starting Trikafta

Reducing the use of supportive therapies after starting Trikafta (elexacaftor/tezacaftor/ivacaftor) didn’t negatively impact health outcomes among cystic fibrosis (CF) patients, according to a recent study. Guided by a de-escalation algorithm for safely stopping supportive therapies, patients were able to cut back on such treatments by 50% on average,…

Worse lung function seen for CF children with ADHD symptoms

Children with cystic fibrosis (CF) who also have symptoms of attention-deficit/hyperactivity disorder (ADHD) may experience worse lung function, according to a new study from Israel and Spain. But the study also spotlighted a potentially far-reaching impact from ADHD on CF symptoms and care for children and adults…